Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 365

The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.

Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer

Open access
Yatabe, Yasushi, Dacic, Sanja, Borczuk, Alain C., Warth, Arne, Russell, Prudence A., Lantuejoul, Sylvie, Beasley, Mary Beth, Thunnissen, Erik, Pelosi, Giuseppe, Rekhtman, Natasha, Bubendorf, Lukas, Mino-Kenudson, Mari, Yoshida, Akihiko, Geisinger, Kim R., Noguchi, Masayuki, Chirieac, Lucian R., Bolting, Johan, Chung, Jin-Haeng, Chou, Teh-Ying, Chen, Gang, Poleri, Claudia, Lopez-Rios, Fernando, Papotti, Mauro, Sholl, Lynette M., Roden, Anja C., Travis, William D., Hirsch, Fred R., Kerr, Keith M., Tsao, Ming-Sound, Nicholson, Andrew G., Wistuba, Ignacio, Moreira, Andre L.·2019·Journal of Thoracic Oncology

Abstract

Since the 2015 WHO classification was introduced into clinical practice, the importance of immunohistochemistry (IHC) has figured prominently in lung cancer diagnosis. In addition to distinction of small versus non-small cell carcinoma (NSCC), patients’ treatment of choice is directly linked to histological subtypes of NSCC, which pertains to IHC results, particularly for poorly-differentiated tumors. The use of IHC has improved diagnostic accuracy in the lung carcinoma classification, but the interpretation remains challenging in some instances. Also, pathologists must be aware of many interpretation pitfalls, and the use of IHC should be efficient to spare the tissue for molecular testing. The IASLC Pathology Committee received questions on practical application and interpretation of IHC in lung cancer diagnosis. After discussions in several IASLC Pathology Committee meetings, the issues and caveats were summarized as eleven key questions, which cover common and important diagnostic situations in a daily clinical practice with some relevant challenging queries. The questions included best IHC markers for distinguishing NSCLC subtypes, differences in TTF1 clones, utility of IHC in diagnosing uncommon subtypes of lung cancer and distinguishing primary from metastatic tumors.” This article provides answers and explanations for the key questions about the use of IHC in lung carcinoma diagnosis representing viewpoints of experts in thoracic pathology that should assist the community in the appropriate use of IHC in diagnostic pathology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2018.12.005

Cites

102 of 102 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 102 references

Cited by

See all 365

Metadata

Authors
Yatabe, Y., Dacic, S., Borczuk, A. C., Warth, A., Russell, P. A., Lantuejoul, S., Beasley, M. B., Thunnissen, E., Pelosi, G., Rekhtman, N., Bubendorf, L., Mino-Kenudson, M., Yoshida, A., Geisinger, K. R., Noguchi, M., Chirieac, L. R., Bolting, J., Chung, J.-H., Chou, T.-Y., Chen, G., Poleri, C., Lopez-Rios, F., Papotti, M., Sholl, L. M., Roden, A. C., Travis, W. D., Hirsch, F. R., Kerr, K. M., Tsao, M.-S., Nicholson, A. G., Wistuba, I., & Moreira, A. L.
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2019-03
Volume
14
Issue
3
Pages
377-407
ISSN
1556-0864 (ISSN-L)
OpenAlex
W2903909248
Cited by
365
References
102
FWCI
20.12
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. https://app.cochat.ai/papers/10.1016/j.jtho.2018.12.005
The paper
Yatabe, Y., Dacic, S., Borczuk, A. C., Warth, A., Russell, P. A., Lantuejoul, S., Beasley, M. B., Thunnissen, E., Pelosi, G., Rekhtman, N., Bubendorf, L., Mino-Kenudson, M., Yoshida, A., Geisinger, K. R., Noguchi, M., Chirieac, L. R., Bolting, J., Chung, J.-H., Chou, T.-Y., . . . Moreira, A. L. (2019). Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2018.12.005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.